Clinical Trial: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07849894) titled 'A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.' on Sept. 24.

Brief Summary: The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy participants.

Study Start Date: June 23, 2017

Study Type: INTERVENTIONAL

Condition: Mild to Moderate Psoriasis Healthy Volunteers

Intervention: DRUG: UCB0159

Different dosages will be ...